Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Matthew R. Sydes"'
Autor:
Natalia Klimowska-Nassar, Matthew R. Sydes, Tim Dudderidge, Puja Jadav, Stuart McCracken, Deepika Reddy, Hashim U. Ahmed, Emily Day, John Staffurth, Mathias Winkler, Thiagarajah Sasikaran, A Toby Prevost, Vincent Khoo, Francesca Fiorentino, Taimur T. Shah
Publikováno v:
Trials
Trials, Vol 22, Iss 1, Pp 1-12 (2021)
Trials, Vol 22, Iss 1, Pp 1-12 (2021)
Background Randomised controlled trials (RCTs) for surgical interventions have often proven difficult with calls for innovative approaches. The Imperial Prostate (IP4) Comparative Health Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025b9d7a53037d1dccb24e19f41e64e8
https://eprints.soton.ac.uk/455681/
https://eprints.soton.ac.uk/455681/
Publikováno v:
European Urology Focus. 5:125-133
Context Androgen deprivation therapy (ADT) is the standard of care for men with metastatic hormone-sensitive prostate cancer (HSPC) and a potential treatment option in those with prostate-specific antigen relapse after local therapy. Based on promisi
Autor:
Babak Choodari-Oskooei, Daniel J. Bratton, Matthew R. Sydes, Mahesh K.B. Parmar, Angela M. Meade, Melissa Gannon
Publikováno v:
Clinical Trials (London, England)
Background: Experimental treatments pass through various stages of development. If a treatment passes through early-phase experiments, the investigators may want to assess it in a late-phase randomised controlled trial. An efficient way to do this is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc1485c4eab805219a3ce7002339f7b0
https://researchonline.lshtm.ac.uk/id/eprint/4660697/7/Choodari-Oskooei_etal_2020_Adding-new-experimental-arms-to.pdf
https://researchonline.lshtm.ac.uk/id/eprint/4660697/7/Choodari-Oskooei_etal_2020_Adding-new-experimental-arms-to.pdf
Autor:
Thomas Hambrock, Christopher D. Brawley, Alexander Hoyle, Claire Amos, Mahesh K. B. Parmar, Nicholas D. James, Hassan Douis, Aine M Haran, Yatin Jain, J. Calvert, Adnan Ali, Matthew R. Sydes, Gerhardt Attard, Noel W. Clarke
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:Current metastatic burden definitions do not account for lymph node metastases (LNM) (location, size or number). Ongoing and planned metastasis directed therapy trials al...
Autor:
Alex Hoyle, Y. Jain, M.K.B. Parmar, Nicholas D. James, Claire Amos, Matthew R. Sydes, N.W. Clarke, A.M. Haran, T. Hambrock, Adnan Ali
Publikováno v:
European Urology Open Science, Vol 20, Iss, Pp S18-(2020)
Autor:
Christina Wong, Karen Gibbon, C. Green, Daniel J. Bratton, Margaret E. Cruickshank, Hazel Bell, Matthew R. Sydes, Kim S Thomas, R.C. Simpson, Helen Nankervis, Shaheen Haque, Ruth Murphy, Kate London, Shelley Dowey, C. M. Owen, Sally R. Wilkes
Publikováno v:
Journal of lower genital tract disease. 22(4)
Autor:
Noel W. Clarke, Duncan C. Gilbert, Ruth E Langley, Trinh Duong, Anna Bara, Matthew R. Sydes, Paul D. Abel, Max Parmar, Nicholas D. James
Publikováno v:
BJU international. 121(5)
Androgen deprivation therapy (ADT) remains a cornerstone of the management of prostate cancer. The addition of ADT to radiotherapy improves disease-free and overall survival in the locally advanced setting and ADT forms the backbone onto which additi
Publikováno v:
The New England journal of medicine. 377(17)
Autor:
Michael Brundage, Charles Hayter, J. Hetherington, Jinka Sathya, Malcolm David Mason, John Anderson, Jim Barber, Mary Gospodarowicz, Salah El-Sharkawi, Michael McKenzie, Padraig Warde, Matthew R. Sydes, P.D. John Hardman, Luis Souhami, Peter Kirkbride, Edmund C. Kostashuk, Richard A Cowan, Gregory P. Swanson, Mahesh K. B. Parmar, Gordana Jovic, Wendy R. Parulekar, Andrea Hiltz, Bingshu E. Chen
Publikováno v:
Journal of Clinical Oncology
Purpose We have previously reported that radiotherapy (RT) added to androgen-deprivation therapy (ADT) improves survival in men with locally advanced prostate cancer. Here, we report the prespecified final analysis of this randomized trial. Patients
Autor:
Tony W. Ho, Ian F. Tannock, Amit M. Oza, Diana T Chingos, Matthew R. Sydes, Stan B. Kaye, Katherine Karakasis, Deborah Collyar, Michelle K. Wilson, Michael Friedlander, Mahesh K. B. Parmar
Publikováno v:
The Lancet Oncology. 16:e43-e52
Cancer is not one disease. Outcomes and endpoints in trials should incorporate the therapeutic modality and cancer type because these factors affect clinician and patient expectations. In this Review, we discuss how to: define the importance of endpo